CHRS vs MRK
CHRS: A specialized immuno-oncology company driving growth through its FDA-approved PD-1 inhibitor LOQTORZI and a clinical-stage pipeline targeting immune resistance in solid tumors. MRK: Merck & Co. is a leading global biopharmaceutical firm dedicated to delivering life-saving vaccines and innovative therapeutic medicines for major disease areas.
Side-by-side fundamentals
| Metric | CHRS | MRK | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $1.00 | $148.30 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-20) | $155M | $365.9B | |
| P/E as of 2026-10-20 | n/a | 118.64 | |
| Net margin FY2025, SEC XBRL | n/a | +28.1% | |
| ROE FY2025, SEC XBRL | +275.4% | +34.7% | CHRS higher |
| ROA FY2025, SEC XBRL | +65.0% | +13.3% | CHRS higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 1.29 | |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +1.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +3.1% | |
| Dividend yield as of 2026-09-03 | n/a | +2.3% | |
| Dividend streak (yrs) SEC XBRL | 0 | 19 | MRK higher |
| Beta as of 2026-09-03 | 1.50 | 0.29 | |
| 1-year return as of 2026-10-20 close | -44.1% | +71.8% | MRK higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.